Literature DB >> 23647723

Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review.

Janet M Schloss1, Maree Colosimo, Caroline Airey, Paul P Masci, Anthony W Linnane, Luis Vitetta.   

Abstract

Chemotherapy induced peripheral neuropathy [CIPN] is a common significant and debilitating side effect resulting from the administration of neurotoxic chemotherapeutic agents. These pharmaco-chemotherapeutics can include taxanes, vinca alkaloids and others. Moderate to severe CIPN significantly decreases the quality of life and physical abilities of cancer patients and current pharmacotherapy for CIPN e.g. Amifostine and antidepressants have had limited efficacy and may themselves induce adverse side effects. To determine the potential use of nutraceuticals i.e. vitamin E, acetyl-L-carnitine, glutamine, glutathione, vitamin B6, omega-3 fatty acids, magnesium, calcium, alpha lipoic acid and n-acetyl cysteine as adjuvants in cancer treatments a systematic literature review was conducted. Revised clinical studies comprised of randomized clinical trials that investigated the anti-CIPN effect of nutraceuticals as the adjuvant intervention in patients administered chemotherapy. Twenty-four studies were assessed on methodological quality and limitations identified. Studies were mixed in their recommendations for nutraceuticals. Currently no agent has shown solid beneficial evidence to be recommended for the treatment or prophylaxis of CIPN. The standard of care for CIPN includes dose reduction and/or discontinuation of chemotherapy treatment. The management of CIPN remains an important challenge and future studies are warranted before recommendations for the use of supplements can be made.
Copyright © 2013 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  CIPN; Chemotherapy induced peripheral neuropathy; Nutraceuticals; Vitamins

Mesh:

Substances:

Year:  2013        PMID: 23647723     DOI: 10.1016/j.clnu.2013.04.007

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  34 in total

Review 1.  Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives.

Authors:  Robson da Costa; Giselle F Passos; Nara L M Quintão; Elizabeth S Fernandes; João Raphael L C B Maia; Maria Martha Campos; João B Calixto
Journal:  Br J Pharmacol       Date:  2020-06-03       Impact factor: 8.739

2.  Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer.

Authors:  Desiree Jones; Fengmin Zhao; Joanna Brell; Mark A Lewis; Charles L Loprinzi; Matthias Weiss; Michael J Fisch
Journal:  J Cancer Surviv       Date:  2014-07-15       Impact factor: 4.442

3.  Chemotherapy-induced peripheral neuropathy (CIPN) and vitamin B12 deficiency.

Authors:  Janet M Schloss; Maree Colosimo; Caroline Airey; Luis Vitetta
Journal:  Support Care Cancer       Date:  2015-04-12       Impact factor: 3.603

Review 4.  Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.

Authors:  Sang Hui Chu; Young Joo Lee; Eon Sook Lee; Yimin Geng; Xin Shelley Wang; Charles S Cleeland
Journal:  Support Care Cancer       Date:  2014-09-26       Impact factor: 3.603

5.  Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).

Authors:  Shailly Mehrotra; Manish R Sharma; Elizabeth Gray; Kehua Wu; William T Barry; Clifford Hudis; Eric P Winer; Alan P Lyss; Deborah L Toppmeyer; Alvaro Moreno-Aspitia; Thomas E Lad; Mario Valasco; Beth Overmoyer; Hope Rugo; Mark J Ratain; Jogarao V Gobburu
Journal:  AAPS J       Date:  2017-06-15       Impact factor: 4.009

Review 6.  Animal models of peripheral neuropathy due to environmental toxicants.

Authors:  Deepa B Rao; Bernard S Jortner; Robert C Sills
Journal:  ILAR J       Date:  2014

Review 7.  Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source.

Authors:  Jiacheng Ma; Annemieke Kavelaars; Patrick M Dougherty; Cobi J Heijnen
Journal:  Cancer       Date:  2018-02-20       Impact factor: 6.860

8.  Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.

Authors:  Ying Guo; Desiree Jones; J Lynn Palmer; Arthur Forman; Shaker R Dakhil; Maria R Velasco; Matthias Weiss; Paul Gilman; G M Mills; Stephen J Noga; Cathy Eng; Michael J Overman; Michael J Fisch
Journal:  Support Care Cancer       Date:  2013-12-22       Impact factor: 3.603

9.  Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale.

Authors:  Tito R Mendoza; Xin Shelley Wang; Loretta A Williams; Qiuling Shi; Elisabeth G Vichaya; Patrick M Dougherty; Sheeba K Thomas; Emre Yucel; Christel C Bastida; Jeanie F Woodruff; Charles S Cleeland
Journal:  J Pain       Date:  2015-07-22       Impact factor: 5.820

10.  A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).

Authors:  Janet M Schloss; Maree Colosimo; Caroline Airey; Paul Masci; Anthony W Linnane; Luis Vitetta
Journal:  Support Care Cancer       Date:  2016-09-09       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.